ASP015K

DRUG16 trials

Sponsors

Astellas Pharma Inc, Astellas Pharma Global Development, Inc.

Conditions

Bioavailability of ASP015KDrug InteractionsFood Effect of ASP015KHealthyHealthy SubjectsHealthy VolunteersPatients With Impaired Hepatic FunctionPatients With Impaired Renal Function

Phase 1

A Study to Assess Drug Interaction of ASP015K and Midazolam

CompletedNCT01182077

Astellas Pharma IncHealthy, Pharmacokinetics of ASP015K and Midazolam

Start: 2010-06-30End: 2010-07-31Updated: 2010-08-16

A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus

CompletedNCT01190670

Astellas Pharma IncHealthy, Pharmacokinetics of ASP015K and Tacrolimus

Start: 2010-07-31End: 2010-09-30Updated: 2010-10-14

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

CompletedNCT01364974

Astellas Pharma IncHealthy Subjects, Pharmacodynamics, Pharmacokinetics of ASP015K

Start: 2009-01-31End: 2009-05-31Updated: 2011-06-03

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers

CompletedNCT01364987

Astellas Pharma IncDrug Interactions, Healthy Subjects, Pharmacokinetics of ASP015K

Start: 2009-05-31End: 2009-06-30Updated: 2011-06-03

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

CompletedNCT01387087

Astellas Pharma IncHealthy Subjects, Pharmacokinetics of ASP015K

Start: 2008-07-31End: 2008-11-30Updated: 2011-07-04

A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male Subjects

CompletedNCT01406132

Astellas Pharma IncHealthy Subjects, Pharmacokinetics of ASP015K

Start: 2009-12-31End: 2010-01-31Updated: 2011-08-01

Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy Volunteers

CompletedNCT01430065

Astellas Pharma IncDrug Interactions, Healthy Subjects, Pharmacokinetics of ASP015K

Start: 2009-06-30End: 2009-06-30Updated: 2011-09-07

A Study to Assess the Bioavailability of ASP015K

CompletedNCT01430078

Astellas Pharma IncHealthy

Start: 2010-09-30End: 2010-10-31Updated: 2011-09-07

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

CompletedNCT01484964

Astellas Pharma IncBioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K

Start: 2011-09-30End: 2011-10-31Updated: 2011-12-05

A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

CompletedNCT01486017

Astellas Pharma IncBioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K

Start: 2011-09-30End: 2011-09-30Updated: 2011-12-06

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

CompletedNCT01929577

Astellas Pharma Global Development, Inc.Bioavailability of ASP015K, Food Effect of ASP015K, Healthy Subjects +1

Start: 2013-05-31End: 2013-08-31Updated: 2013-09-16

Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin

CompletedNCT01959399

Astellas Pharma Global Development, Inc.Healthy Subjects, Pharmacokinetics of ASP015K

Start: 2013-05-31End: 2013-07-31Updated: 2013-10-10

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

CompletedNCT02111317

Astellas Pharma Global Development, Inc.Healthy Subjects, Pharmacokinetics of ASP015K

Start: 2013-10-31End: 2013-11-30Updated: 2014-04-11

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects

CompletedNCT02141425

Astellas Pharma Global Development, Inc.Healthy Volunteers, Pharmacokinetics of ASP015K

Start: 2014-03-31End: 2014-04-30Updated: 2014-06-04

Pharmacokinetics Study in Patients With Impaired Hepatic Function

CompletedNCT02586194

Astellas Pharma IncPatients With Impaired Hepatic Function

Start: 2015-12-28End: 2016-09-27Updated: 2024-10-16

Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function

CompletedNCT02603497

Astellas Pharma IncPatients With Impaired Renal Function

Start: 2015-11-24End: 2016-12-19Updated: 2024-10-16

Related Papers

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function

Clinical Drug Investigation2019-11-1515 citations

Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.

2017-07-019 citations